FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600553571> ?p ?o ?g. }

• W2600553571 abstract "In definitive radiation therapy for head and neck cancer, clinically uninvolved cervical lymph nodes are irradiated with a so-called ‘elective dose’ in order to achieve control of clinically occult metastases. As a consequence of high-resolution diagnostic imaging, occult tumor volume has significantly decreased in the last decades. Since the elective dose is dependent on occult tumor volume, the currently used elective dose may be higher than necessary. Because bilateral irradiation of the neck contributes to dysphagia, xerostomia and hypothyroidism in a dose dependent way, dose de-escalation to these regions can open a window of opportunity to reduce toxicity and improve quality of life after treatment. UPGRADE-RT is a multicenter, phase III, single-blinded, randomized controlled trial. Patients to be treated with definitive radiation therapy for a newly diagnosed stage T2-4 N0-2 M0 squamous cell carcinoma of the oropharynx, hypopharynx or larynx are eligible. Exclusion criteria are recurrent disease, oncologic surgery to the head and neck area, concomitant chemotherapy or epidermal growth factor receptor inhibitors. In total, 300 patients will be randomized in a 2:1 ratio to a treatment arm with or without de-escalation of the elective radiation dose and introduction of an intermediate dose-level for selected lymph nodes. Radiation therapy planning FDG-PET/CT-scans will be acquired to guide risk assessment of borderline-sized cervical nodes that can be treated with the intermediate dose level. Treatment will be given with intensity-modulated radiation therapy or volumetric arc therapy with simultaneous-integrated boost using an accelerated fractionation schedule, 33 fractions in 5 weeks. The primary endpoint is ‘normalcy of diet’ at 1 year after treatment (toxicity). The secondary endpoint is the actuarial rate of recurrence in electively irradiated lymph nodes at 2 years after treatment (safety). The objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective radiation dose and the introduction of an intermediate dose-level for borderline sized lymph nodes in the treatment of head and neck cancer will result in less radiation sequelae and improved quality of life after treatment without compromising the recurrence rate in the electively treated neck. ClinicalTrials.gov Identifier: NCT02442375 ." @default.
• W2600553571 created "2017-04-07" @default.
• W2600553571 creator A5000396669 @default.
• W2600553571 creator A5009217884 @default.
• W2600553571 creator A5017354524 @default.
• W2600553571 creator A5022405517 @default.
• W2600553571 creator A5031603157 @default.
• W2600553571 creator A5041203940 @default.
• W2600553571 creator A5050756461 @default.
• W2600553571 creator A5051610674 @default.
• W2600553571 creator A5063356044 @default.
• W2600553571 creator A5066137686 @default.
• W2600553571 creator A5069087161 @default.
• W2600553571 creator A5078284151 @default.
• W2600553571 date "2017-03-21" @default.
• W2600553571 modified "2023-09-26" @default.
• W2600553571 title "Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma" @default.
• W2600553571 cites W1947168884 @default.
• W2600553571 cites W1982641163 @default.
• W2600553571 cites W1986347930 @default.
• W2600553571 cites W1994747484 @default.
• W2600553571 cites W2004773310 @default.
• W2600553571 cites W2009970513 @default.
• W2600553571 cites W2012708547 @default.
• W2600553571 cites W2015096497 @default.
• W2600553571 cites W2016524159 @default.
• W2600553571 cites W2016756532 @default.
• W2600553571 cites W2016871222 @default.
• W2600553571 cites W2043945205 @default.
• W2600553571 cites W2057691621 @default.
• W2600553571 cites W2072739151 @default.
• W2600553571 cites W2081365004 @default.
• W2600553571 cites W2088783247 @default.
• W2600553571 cites W2091406619 @default.
• W2600553571 cites W2105150213 @default.
• W2600553571 cites W2112884386 @default.
• W2600553571 cites W2118772763 @default.
• W2600553571 cites W2127151679 @default.
• W2600553571 cites W2128752314 @default.
• W2600553571 cites W2138366863 @default.
• W2600553571 cites W2146552670 @default.
• W2600553571 cites W2148517717 @default.
• W2600553571 cites W2148754315 @default.
• W2600553571 cites W2167571044 @default.
• W2600553571 cites W2169496348 @default.
• W2600553571 cites W2172288146 @default.
• W2600553571 cites W2194646862 @default.
• W2600553571 cites W2398529328 @default.
• W2600553571 cites W2419490962 @default.
• W2600553571 cites W2617766691 @default.
• W2600553571 cites W2835311398 @default.
• W2600553571 doi "https://doi.org/10.1186/s12885-017-3195-7" @default.
• W2600553571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5361684" @default.
• W2600553571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28327089" @default.
• W2600553571 hasPublicationYear "2017" @default.
• W2600553571 type Work @default.
• W2600553571 sameAs 2600553571 @default.
• W2600553571 citedByCount "24" @default.
• W2600553571 countsByYear W26005535712017 @default.
• W2600553571 countsByYear W26005535712018 @default.
• W2600553571 countsByYear W26005535712019 @default.
• W2600553571 countsByYear W26005535712020 @default.
• W2600553571 countsByYear W26005535712021 @default.
• W2600553571 countsByYear W26005535712022 @default.
• W2600553571 countsByYear W26005535712023 @default.
• W2600553571 crossrefType "journal-article" @default.
• W2600553571 hasAuthorship W2600553571A5000396669 @default.
• W2600553571 hasAuthorship W2600553571A5009217884 @default.
• W2600553571 hasAuthorship W2600553571A5017354524 @default.
• W2600553571 hasAuthorship W2600553571A5022405517 @default.
• W2600553571 hasAuthorship W2600553571A5031603157 @default.
• W2600553571 hasAuthorship W2600553571A5041203940 @default.
• W2600553571 hasAuthorship W2600553571A5050756461 @default.
• W2600553571 hasAuthorship W2600553571A5051610674 @default.
• W2600553571 hasAuthorship W2600553571A5063356044 @default.
• W2600553571 hasAuthorship W2600553571A5066137686 @default.
• W2600553571 hasAuthorship W2600553571A5069087161 @default.
• W2600553571 hasAuthorship W2600553571A5078284151 @default.
• W2600553571 hasBestOaLocation W26005535711 @default.
• W2600553571 hasConcept C126838900 @default.
• W2600553571 hasConcept C141071460 @default.
• W2600553571 hasConcept C155806632 @default.
• W2600553571 hasConcept C168563851 @default.
• W2600553571 hasConcept C2776530083 @default.
• W2600553571 hasConcept C2776833033 @default.
• W2600553571 hasConcept C2779384505 @default.
• W2600553571 hasConcept C2989005 @default.
• W2600553571 hasConcept C509974204 @default.
• W2600553571 hasConcept C71924100 @default.
• W2600553571 hasConceptScore W2600553571C126838900 @default.
• W2600553571 hasConceptScore W2600553571C141071460 @default.
• W2600553571 hasConceptScore W2600553571C155806632 @default.
• W2600553571 hasConceptScore W2600553571C168563851 @default.
• W2600553571 hasConceptScore W2600553571C2776530083 @default.
• W2600553571 hasConceptScore W2600553571C2776833033 @default.
• W2600553571 hasConceptScore W2600553571C2779384505 @default.
• W2600553571 hasConceptScore W2600553571C2989005 @default.
• W2600553571 hasConceptScore W2600553571C509974204 @default.
• W2600553571 hasConceptScore W2600553571C71924100 @default.
• W2600553571 hasFunder F4320322777 @default.

• next